Achilles Therapeutics PL-ADRACHL
13F holders, Q4 2024 (December 31)At the end of Q4 2024, 21 institutions reported holding Achilles Therapeutics PL-ADR (ACHL) in their 13F filings, down 1 from Q3 2024. 3 opened new positions and 5 sold out. The largest holders were Syncona Portfolio Ltd ($12.6M), BML Capital Management, LLC ($4.7M) and FCPM III Services B.V. ($2.7M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Achilles Therapeutics PL-ADR
- CUSIP
- 00449L102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $106K |
| Exits | 5 | $47K |
All 13F filers, Q3 2024 → Q4 2024: 162,300 shares bought and 203,609 shares sold, net −41,309 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 21 holders
| Syncona Portfolio Ltd | 23.86% | No change | 11,086,909 | $12.6M |
| BML Capital Management, LLC | 2.90% | No change | 4,100,002 | $4.7M |
| FCPM III Services B.V. | 0.46% | No change | 2,390,050 | $2.7M |
| Redmile Group, LLC | 0.13% | No change | 1,608,089 | $1.8M |
| Vestal Point Capital, LP | 0.10% | No change | 1,500,000 | $1.7M |
| Ikarian Capital, LLC | 0.47% | Reduce -0.1% | 1,441,141 | $1.6M |
| Siren, L.L.C. | 0.04% | No change | 755,375 | $861K |
| Renaissance Technologies | 0.00% | Reduce -14.2% | 547,233 | $624K |
| Boothbay Fund Management, LLC | 0.02% | Reduce -0.5% | 418,441 | $477K |
| Acadian Asset Management LLC | 0.00% | Reduce -23.5% | 191,829 | $218K |
| Two Sigma Investments, LP | 0.00% | Add +190.1% | 61,637 | $70K |
| BNP Paribas Financial Markets | 0.00% | New | 50,189 | $57K |
| Two Sigma Advisers, LP | 0.00% | Add +52.7% | 34,200 | $39K |
| Morgan Stanley | 0.00% | Add +105.3% | 33,731 | $38K |
| XTX Topco Ltd | 0.00% | New | 26,824 | $31K |
| Geode Capital Management, LLC | 0.00% | No change | 21,590 | $25K |
| Citadel Advisors | 0.00% | New | 15,799 | $18K |
| Brave Asset Management Inc. | 0.00% | No change | 10,000 | $11K |
| Rhumbline Advisers | 0.00% | No change | 4,480 | $5K |
| SBI Securities Co., Ltd. | 0.00% | — | 322 | $367 |
| JPMorgan Chase & Co. | 0.00% | No change | 137 | $156 |
"% of holder's portfolio" is ACHL's weight in each manager's 13F, not the share of Achilles Therapeutics PL-ADR the manager owns.